Tokyo Tape
Sign in
← Olympus

Quarterly report · Q2

7733.TEDINET S100S68V
Period2023-04-01 → 2023-09-30
Filed2023-11-09
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥436.6bn2023-04-01 → 2023-09-30Cons.Revenue IFRS (5-year summary)
Revenue¥228.9bn2023-07-01 → 2023-09-30dCons.Revenue IFRS (5-year summary)
Revenue¥881.9bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥417.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS (5-year summary)
Revenue¥224.8bn2022-07-01 → 2022-09-30dCons.Revenue IFRS (5-year summary)
Operating income¥4.8bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income−¥17.7bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥93.6bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥49.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax−¥958m2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥20.7bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥182.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥89.3bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥47.3bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥216.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥24.3bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥143.4bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥66.8bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥42.0bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥216.7bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income−¥24.0bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥66.9bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥42.0bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥1.62Tat 2023-09-30Cons.Assets IFRS
Total assets¥1.51Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.49Tat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥790.2bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥867.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥827.5bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥641.2bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥644.1bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥511.4bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥827.5bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥640.1bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥643.0bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥488.2bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥169.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.5bnat 2023-03-31Cons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥297.4bnat 2022-09-30Cons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow−¥11.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥98.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥412.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥58.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥15.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥125.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥143.2bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥35.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥173.812023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-19.642023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥113.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥52.52022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.972022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥173.432023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-19.62023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥113.082022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥52.452022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥32.932022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio51.2%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio42.4%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio43.3%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥18.6bn
jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30¥50.9bn
jpcrp040300-q2r_E02272-000Otherreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥28.5bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥23.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥4.3bn
jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥68.9bn
jpcrp040300-q2r_E02272-000Otherreportable segmentsegment profit2022-04-01 → 2022-09-30−¥788m
jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥29.8bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥97.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 781
ItemContextValueUnit
Dividends paid to non controlling interests fin cf IFRSPrior1YTDDuration-226000000JPY
Dividends paid to non controlling interests fin cf IFRSCurrentYTDDuration-183000000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-2000000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-63976000000JPY
Decrease increase in deposit for purchase of treasury shares fin cf IFRSPrior1YTDDuration－JPY
Decrease increase in deposit for purchase of treasury shares fin cf IFRSCurrentYTDDuration-26024000000JPY
Redemption of bonds fin cf IFRSPrior1YTDDuration-10000000000JPY
Redemption of bonds fin cf IFRSCurrentYTDDuration－JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1YTDDuration－JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSCurrentYTDDuration-2921000000JPY
Other fin cf IFRSPrior1YTDDuration2263000000JPY
Other fin cf IFRSCurrentYTDDuration-2092000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-35452000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-125422000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration39615000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration7146000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-5183000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration282648000000JPY
Cash and cash equivalents if different from bs balance IFRSPrior2YearInstant302572000000JPY
Cash and cash equivalents if different from bs balance IFRSPrior1YearInstant205512000000JPY
Cash and cash equivalents if different from bs balance IFRSPrior1QuarterInstant297389000000JPY
Cash and cash equivalents if different from bs balance IFRSCurrentQuarterInstant488160000000JPY
Sales to external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember258472000000JPY
Sales to external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember152935000000JPY
Sales to external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember5653000000JPY
Sales to external customers IFRSPrior1YTDDuration_ReportableSegmentsMember417060000000JPY
Sales to external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Sales to external customers IFRSPrior1YTDDuration417060000000JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember－JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember－JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember162000000JPY
Intersegment sales IFRSPrior1YTDDuration_ReportableSegmentsMember162000000JPY
Intersegment sales IFRSPrior1YTDDuration_ReconcilingItemsMember-162000000JPY
Intersegment sales IFRSPrior1YTDDuration－JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember258472000000JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember152935000000JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember5815000000JPY
Net sales IFRSPrior1YTDDuration_ReportableSegmentsMember417222000000JPY
Net sales IFRSPrior1YTDDuration_ReconcilingItemsMember-162000000JPY
Net sales IFRSPrior1YTDDuration417060000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember68899000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember29788000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember-788000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember97899000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-4296000000JPY
Operating profit loss IFRSPrior1YTDDuration93603000000JPY
Finance income IFRSPrior1YTDDuration1764000000JPY
Finance costs IFRSPrior1YTDDuration6046000000JPY
Profit loss before tax IFRSPrior1YTDDuration89321000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember371000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass